Φορτώνει......
Exploring and comparing adverse events between PARP inhibitors
Ovarian cancer remains one of the most challenging malignancies to treat. Targeted therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as one of the most exciting new treatments for ovarian cancer, particularly in women with BRCA1 or BRCA2 mutations or those without a funct...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Lancet Oncol |
|---|---|
| Κύριοι συγγραφείς: | , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7292736/ https://ncbi.nlm.nih.gov/pubmed/30614472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30786-1 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|